Exosome: emerging biomarker in breast cancer

Yunlu Jia; Yongxia Chen; Qinchuan Wang; Ushani Jayasinghe; Xiao Luo; Qun Wei; Ji Wang; Hanchu Xiong; Cong Chen; Bin Xu; Wenxian Hu; Linbo Wang; Wenhe Zhao; Jichun Zhou

doi:10.18632/oncotarget.16684

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Exosome: emerging biomarker in breast cancer

Yunlu Jia, Yongxia Chen, Qinchuan Wang, Ushani Jayasinghe, Xiao Luo, Qun Wei, Ji Wang, Hanchu Xiong, Cong Chen, Bin Xu, Wenxian Hu, Linbo Wang _, Wenhe Zhao and Jichun Zhou

PDF | HTML | How to cite

Oncotarget. 2017; 8:41717-41733. https://doi.org/10.18632/oncotarget.16684

Metrics: PDF 11406 views | HTML 12987 views | ?

Abstract

Yunlu Jia1,2, Yongxia Chen1,2, Qinchuan Wang1,2, Ushani Jayasinghe3, Xiao Luo4, Qun Wei1,2, Ji Wang1,2, Hanchu Xiong1,2, Cong Chen1,2, Bin Xu1,2, Wenxian Hu1,2, Linbo Wang1,2, Wenhe Zhao1,2 and Jichun Zhou1,2

1 Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China

2 Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, Zhejiang, China

3 Brown University, Providence, Rhode Island, USA

4 Department of Radiology, Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China

Correspondence to:

Linbo Wang, email:

Wenhe Zhao, email:

Jichun Zhou, email:

Keywords: breast cancer, exosome, metastasis, drug resistance, cancer therapy

Received: January 10, 2017 Accepted: March 10, 2017 Published: March 29, 2017

Abstract

Exosomes are nano-sized membrane vesicles released by a variety of cell types, and are thought to play important roles in intercellular communications. In breast cancer, through horizontal transfer of various bioactive molecules, such as proteins and mRNAs, exosomes are emerging as local and systemic cell-to-cell mediators of oncogenic information and play an important role on cancer progression. This review outlines the current knowledge and concepts concerning the exosomes involvement in breast cancer pathogenesis (including tumor initiation, invasion and metastasis, angiogenesis, immune system modulation and tumor microenvironment) and cancer therapy resistance. Moreover, the potential use of exosomes as promising diagnostic and therapeutic biomarkers in breast cancer are also discussed.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16684

Publication Alerts

Reviews:

Exosome: emerging biomarker in breast cancer

Abstract